After Remdesivir, second drug disappoints in Covid-19 trial – New Straits Times Online
- After Remdesivir, second drug disappoints in Covid-19 trial New Straits Times Online
- Closely watched arthritis drug disappoints in Covid-19 trial The Star Online
- After disappointing early numbers, Sanofi and Regeneron scale back Kevzara’s COVID-19 test FiercePharma
- Coronavirus Treatment: Arthritis Drug Mixed In Covid-19; Gilead’s Remdesivir Considered In Japan Investor’s Business Daily
- Positive Cancer Trial Results Offset a COVID-19 Flop for Regeneron and Sanofi The Motley Fool
- View Full coverage on Google News
Source: Business News Feed